Clinical Trial Update: Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B [Phase 3]

View source ↗

Summary

Phase 3 trial investigating a recombinant botulinum vaccine (A/B) for botulism was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Botulism

Drugs mentioned

• Recombinant Botulinum Vaccine A/B

Snippet

Sponsor: DynPort Vaccine Company LLC, A GDIT Company | Conditions: Botulism | Phase 3 | Status: WITHDRAWN